The initial phase of the collaboration will focus on the discovery and characterization of genetic markers relating to this disease. On successful completion of the first phase of this collaboration, a key aim thereafter will be to develop diagnostic predictors for use in Ipsen’s clinical trials, which would potentially form the basis for commercial companion diagnostic tests for Ipsen’s short stature therapies.
Celera will receive an undisclosed payment for the initial phase of this multi-year collaboration, and any future payment will depend on success of the initial phase.
Jacques-Pierre Moreau, executive vice-president and chief scientific officer of Ipsen, said: “Celera’s leadership in the field of genomics as applied to diagnostic and prognostic assays is expected to support Ipsen’s effort towards the optimal use of its hormone replacement medicines for the treatment of short stature. The potential outcomes from this collaboration could lead to the development of tests to support the rationale for use of our products in novel indications for short stature.”